Suppression of metastasis by mirtazapine via restoration of the Lin-7C/Î 2-catenin pathway in human cancer cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Uzawa, Katsuhiro ^a,b   Kasamatsu, Atsushi ^b   Shimizu, Toshihiro ^a   Saito, Yasuhiro ^a   Baba, Takao ^a   Sakuma, Kentaro ^a   Fushimi, Kazuaki ^a   Sakamoto, Yosuke ^b   Ogawara, Katsunori ^b   Shiiba, Masashi ^a   Tanzawa, Hideki ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CATENIN; LIN-7 PROTEIN, MAMMALIAN; MEMBRANE PROTEIN; MIANSERIN; MIRTAZAPINE; SEROTONIN 2C RECEPTOR;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOBLOTTING; MELANOMA; METABOLISM; METASTASIS; NEOPLASMS; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MELANOMA; MEMBRANE PROTEINS; MIANSERIN; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS; RECEPTOR, SEROTONIN, 5-HT2C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903455840     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05433     Document Type: Article

References (27)

1. Xu, L. et al. Aberrant expression of beta-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer. Hum Pathol 44, 1357-1364 (2013).
2. Arozarena, I. et al. In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30, 4531-4543 (2011).
3. Takahashi, Y., Nishikawa, M., Suehara, T., Takiguchi, N. & Takakura, Y. Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int J Cancer 123, 2315-2320 (2008).
4. Ogoshi, K. et al. Dickkopf-1 in human oral cancer. Int J Oncol 39, 329-336 (2011).
5. Onda, T. et al. Lin-7C/VELI3/MALS-3: an essential component in metastasis of human squamous cell carcinoma. Cancer Res 67, 9643-9648 (2007). (Pubitemid 47621210)
6. Polakis, P. Wnt signaling and cancer. Genes Dev 14, 1837-1851 (2000). (Pubitemid 30639518)
7. Bankfalvi, A. et al. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 198, 343-351 (2002). (Pubitemid 35277385)
8. Saito, Y., Takazawa, H., Uzawa, K., Tanzawa, H. & Sato, K. Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 59 CpG island. Int J Oncol 12, 293-298 (1998).
9. Perego, C. et al. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci 115, 3331-3340 (2002). (Pubitemid 34960185)
10. Cha, J. D., Kim, H. J. & Cha, I. H. Genetic alterations in oral squamous cell carcinoma progression detected by combining array-based comparative genomic hybridization and multiplex ligation-dependent probe amplification. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111, 594-607 (2011).
11. Wang, Q. et al. CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. Cancer Lett 179, 71-77 (2002). (Pubitemid 34195655)
12. Martinez-Estrada, O. M. et al. Association of junctional adhesion molecule with calcium/calmodulin-dependent serine protein kinase (CASK/LIN-2) in human epithelial caco-2 cells. J Biol Chem 276, 9291-9296 (2001).
13. Giangreco, A., Jensen, K. B., Takai, Y., Miyoshi, J. & Watt, F. M. Necl2 regulates epidermal adhesion and wound repair. Development 136, 3505-3514 (2009).
14. Marquez-Rosado, L., Singh, D., Rincon-Arano, H., Solan, J. L. & Lampe, P. D. CASK (LIN2) interacts with Cx43 in wounded skin and their coexpression affects cell migration. J Cell Sci 125, 695-702 (2012).
15. Xie, X. K., Yang, D. S., Ye, Z. M. & Tao, H. M. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines. Chemotherapy 55, 433-440 (2009).
16. Kimura, H. et al. Caffeine-potentiated chemotherapy for metastatic osteosarcoma. J Orthop Sci 14, 556-565 (2009).
17. Miwa, S. et al. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-kappaB and MAPK pathways. Anticancer Res 32, 3643-3649 (2012).
18. Anttila, S. A. & Leinonen, E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7, 249-264 (2001). (Pubitemid 34016084)
19. Millan, M. J. et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12, 1079-1095 (2000). (Pubitemid 30168787)
20. Pan, C. C. et al. The antidepressant mirtazapine-induced cytosolic Ca21 elevation and cytotoxicity in human osteosarcoma cells. Chin J Physiol 49, 290-297 (2006).
21. Fang, C. K. et al. Mirtazapine inhibits tumor growth via immune response and serotonergic system. PLoS ONE 7, e38886 (2012).
22. Muramatsu, H. et al. Superoxide dismutase in SAS human tongue carcinoma cell line is a factor defining invasiveness and cell motility. Cancer Res 55, 6210-6214 (1995).
23. Chanrion, B. et al. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 73, 748-757 (2008).
24. Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303, 815-822 (2002). (Pubitemid 35231258)
25. Conde, S. V. et al. Caffeine inhibition of rat carotid body chemoreceptors is mediatedby A2A and A2B adenosine receptors.J Neurochem 98, 616-628 (2006). (Pubitemid 44133163)
26. Pacchioni, A. M., Gabriele, A., Donovan, J. L., DeVane, C. L. & See, R. E. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. Int J Neuropsychopharmacol 13, 1067-1077 (2010).
27. Megens, A. A. et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 114, 9-23 (1994). (Pubitemid 24150515)